Factors Associated with Cystic Fibrosis Mortality Before the Age of 30: Retrospective Analysis of a Cohort in Southern Brazil

Overview

Journal Braz J Med Biol Res

Specialties Biology
General Medicine

Date 2024 Aug 28

PMID 39194031

Authors

J De Conto

P T R Dalcin

B Ziegler

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to retrospectively evaluate the factors associated with mortality before the age of 30 in adults with cystic fibrosis (CF) followed up at a referral center in southern Brazil. This study included individuals over 18 years of age. Clinical data related to childhood and the period of transition to an adult healthcare of individuals with CF were recorded, as well as spirometric and mortality data of individuals between 18 and 30 years of age. A total of 48 patients were included in this study, of which 28 (58.3%) were male. Comparing groups, we observed a higher prevalence of homozygosis for the F508del mutation (P=0.028), massive hemoptysis before the age of 18 (P=0.027), and lower values of pulmonary function, forced expiratory volume in the first second (FEV1) (%) (P=0.002), forced vital capacity (FVC) (%) (P=0.01), and FEV1/FVC (%) (P=0.001) in the group that died before age 30. F508del homozygosis, episodes of massive hemoptysis in childhood, and lower FEV1 values at age 18 were related to mortality before age 30 in a cohort of individuals with CF in southern Brazil.

References

Simmonds N . Ageing in cystic fibrosis and long-term survival. Paediatr Respir Rev. 2013; 14 Suppl 1:6-9. DOI: 10.1016/j.prrv.2013.01.007. View

Dalcin P, de Abreu E Silva F . Cystic fibrosis in adults: diagnostic and therapeutic aspects. J Bras Pneumol. 2008; 34(2):107-17. DOI: 10.1590/s1806-37132008000200008. View

Rosa K, de Lima E, Machado C, Rispoli T, Silveira V, Ongaratto R . Genetic and phenotypic traits of children and adolescents with cystic fibrosis in Southern Brazil. J Bras Pneumol. 2019; 44(6):498-504. PMC: 6459751. DOI: 10.1590/s1806-37562017000000418. View

Wendekier C, Wendekier-Raybuck K . Cystic fibrosis: A changing landscape. Nurse Pract. 2021; 46(9):48-55. DOI: 10.1097/01.NPR.0000769756.82495.f3. View

Keogh R, Seaman S, Barrett J, Taylor-Robinson D, Szczesniak R . Dynamic Prediction of Survival in Cystic Fibrosis: A Landmarking Analysis Using UK Patient Registry Data. Epidemiology. 2018; 30(1):29-37. PMC: 6276867. DOI: 10.1097/EDE.0000000000000920. View

De Boeck K . Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020; 109(5):893-899. DOI: 10.1111/apa.15155. View

Keogh R, Szczesniak R, Taylor-Robinson D, Bilton D . Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. J Cyst Fibros. 2018; 17(2):218-227. PMC: 5885983. DOI: 10.1016/j.jcf.2017.11.019. View

Ramos K, Smith P, McKone E, Pilewski J, Lucy A, Hempstead S . Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros. 2019; 18(3):321-333. PMC: 6545264. DOI: 10.1016/j.jcf.2019.03.002. View

Simmonds N, MacNeill S, Cullinan P, Hodson M . Cystic fibrosis and survival to 40 years: a case-control study. Eur Respir J. 2010; 36(6):1277-83. DOI: 10.1183/09031936.00001710. View

10.

Vandenbroucke N, Zampoli M, Morrow B . Lung function determinants and mortality of children and adolescents with cystic fibrosis in South Africa 2007-2016. Pediatr Pulmonol. 2020; 55(6):1381-1387. DOI: 10.1002/ppul.24726. View

11.

Kerem E, Viviani L, Zolin A, Macneill S, Hatziagorou E, Ellemunter H . Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J. 2013; 43(1):125-33. DOI: 10.1183/09031936.00166412. View

12.

Spoonhower K, Davis P . Epidemiology of Cystic Fibrosis. Clin Chest Med. 2016; 37(1):1-8. DOI: 10.1016/j.ccm.2015.10.002. View

13.

Southern K, Murphy J, Sinha I, Nevitt S . A systematic cochrane review of corrector therapies (with or without potentiators) for people with cystic fibrosis with class II gene variants (most commonly F508DEL). Paediatr Respir Rev. 2021; 38:33-36. DOI: 10.1016/j.prrv.2021.03.001. View

14.

Espel J, Palac H, Bharat A, Cullina J, Prickett M, Sala M . The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype. J Cyst Fibros. 2017; 17(1):34-42. DOI: 10.1016/j.jcf.2017.11.002. View

15.

Bustamante A, Fernandez L, Rivas L, Mercado-Longoria R . Disparities in cystic fibrosis survival in Mexico: Impact of socioeconomic status. Pediatr Pulmonol. 2021; 56(6):1566-1572. DOI: 10.1002/ppul.25351. View

16.

Pereira C, Sato T, Rodrigues S . New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007; 33(4):397-406. DOI: 10.1590/s1806-37132007000400008. View

17.

King C, Brown A, Aryal S, Ahmad K, Donaldson S . Critical Care of the Adult Patient With Cystic Fibrosis. Chest. 2018; 155(1):202-214. DOI: 10.1016/j.chest.2018.07.025. View

18.

Smith M, McGarry M, Ly N, Zinter M . Outcomes of Children With Cystic Fibrosis Admitted to PICUs. Pediatr Crit Care Med. 2020; 21(10):e879-e887. PMC: 7597545. DOI: 10.1097/PCC.0000000000002358. View

19.

Breuer O, Caudri D, Stick S, Turkovic L . Predicting disease progression in cystic fibrosis. Expert Rev Respir Med. 2018; 12(11):905-917. DOI: 10.1080/17476348.2018.1519400. View

20.

Stephenson A, Sykes J, Stanojevic S, Quon B, Marshall B, Petren K . Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study. Ann Intern Med. 2017; 166(8):537-546. PMC: 5467971. DOI: 10.7326/M16-0858. View